In this article (Clin Cancer Res 2012;18:3100–11), which was published in the June 1, 2012, issue of Clinical Cancer Research (1), the colon cancer cell line HT29 EV (empty vector) and shCA9 95 clones were mistakenly identified and are in fact shCA9 and EV clones derived from HCT116, an alternative colon cancer cell line. Short tandem repeat (STR) analysis was performed using the PowerPlex 18 Primer Kit (Promega). Amplicons were separated by capillary electrophoresis on AbiPrism genetic analyzers. An experienced researcher performed the STR analysis. The STR profile of the HT29 clones is more similar to HCT116 and not to HT29, 89% compared with 39%, respectively. The authors regret this error. The change of cell line has only minor effects on the paper as there is no comparison between cell lines and all comparisons are done within cell line pairs. Each of these includes a control compared against the same cells with the expression of CAIX modulated either by overexpression or by shRNA knockdown. In addition now to the CAIX knockdown comparison with EV in HCT116, this paper also utilizes overexpression of CAIX in HCT116 compared against an HCT116 EV control. Differences between the HCT116 EV clones are likely due to clonal variation. The results, therefore, show comparison of overexpression of CAIX against control and CAIX knockdown against control and remain experimentally valid. The original conclusions remain correct.
Skip Nav Destination
Correction| March 13 2014
Correction: Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy
Online ISSN: 1557-3265
Print ISSN: 1078-0432
©2014 American Association for Cancer Research.
Clin Cancer Res (2014) 20 (6): 1706.
Correction: Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy. Clin Cancer Res 15 March 2014; 20 (6): 1706. https://doi.org/10.1158/1078-0432.CCR-14-0324
Download citation file:
Citing articles via